Skip to content

Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.

Effective immediately, Aspen is taking over the sales, distribution and marketing of a portfolio of dermatology products from Merck, with estimated annual sales of $50 million.

This licensing deal takes Aspen gross annualized sales in Australia and New Zealand to around $230 million, excluding Asia and the proposed Sigma transaction.

The products involved are:

  • Antroquoril
  • Celestone
  • Diprosone
  • Eleuphrat
  • Elocon
  • Novasone
  • Propecia

Please be assured of our ongoing commitment to good customer service and a seamless process, however, should you have any queries, please feel free to contact Aspen at any time.


Content Last Reviewed On July 16, 2018

Scroll To Top